二甲双胍联合抗结核药物治疗成人肺结核促进早期痰菌转阴的随机试验
在印度5个中心开展的随机8周临床试验纳入新诊断培养阳性肺结核患者322例,比较标准抗结核治疗(HREZ)与加用每日1000 mg二甲双胍(MET-HREZ)的疗效。二甲双胍未缩短液体培养痰菌转阴时间(中位42天 vs 41天,HR 0.8,95%CI 0.624-1.019),但8周后空洞病变比例和炎症标志物显著降低。
要点
- 二甲双胍加标准抗结核治疗未加快痰培养转阴(HR 0.8,95%CI 0.624-1.019)。
- 8周后METRIF组X线空洞病变7例(5.3%)vs对照组18例(12.9%),RR 0.42(95%CI 0.18-0.96,P=0.041)。
- METRIF组炎症标志物显著低于对照组,提示可减轻肺组织损伤。
核心结论
- 加用二甲双胍未加快标准抗结核治疗患者的痰培养转阴,但减轻了过度炎症,从而减少肺组织损伤,表现为X线病灶清除更快和炎症标志物降低。
研究设计与样本
- 随机、8周临床试验,2018-2020年在印度5个中心开展。
- 纳入新诊断、培养阳性肺结核患者,随机分为标准抗结核治疗(HREZ,对照组)或标准治疗加每日1000 mg二甲双胍(MET-HREZ,METRIF组),疗程8周。
- 主要终点为8周抗结核治疗期间液体培养痰菌转阴时间;部分患者检测血浆炎症标志物;采用Cox比例风险模型估计转阴时间及预测因素。
- 共随机322例,其中男性239例(74%),胸片双侧病变212例(66%),空洞54例(18%)。
主要发现
- 液体培养痰菌转阴中位时间METRIF组42天 vs 对照组41天(HR 0.8,95%CI 0.624-1.019)。
- 8周抗结核治疗后X线空洞病变METRIF组7例(5.3%)vs对照组18例(12.9%),RR 0.42(95%CI 0.18-0.96,P=0.041)。
- METRIF组炎症标志物显著低于对照组。
- 较高体重指数和较低痰涂片分级与更快的痰培养转阴相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metformin, by reducing intracellular Mycobacterium tuberculosis growth, can be considered an adjunctive therapy to anti-tuberculosis treatment (ATT). We determined whether metformin with standard ATT reduces time to sputum culture conversion and tissue inflammation in adults with pulmonary tuberculosis (PTB). METHODS: In a randomized, 8-week, clinical trial, newly diagnosed, culture-positive PTB patients were randomized to standard ATT (HREZ = control arm) or standard ATT plus daily 1000 mg metformin (MET-HREZ = Metformin with Rifampicin [METRIF] arm) for 8 weeks during 2018-2020 at 5 sites in India. The primary end point was time to sputum culture conversion by liquid culture during 8 weeks of ATT. Plasma inflammatory markers were estimated in a subset. A Cox proportional hazard model was used to estimate time and predictors of culture conversion. RESULTS: Of the 322 patients randomized, 239 (74%) were male, and 212 (66%) had bilateral disease on chest radiograph with 54 (18%) showing cavitation. The median time to sputum culture conversion by liquid culture was 42 days in the METRIF arm and 41 days in the control arm (hazard ratio, 0.8; 95% confidence interval [CI], .624-1.019). After 8 weeks of ATT, cavitary lesions on X-ray (7, 5.3% vs 18, 12.9%; relative risk, 0.42; 95% CI, .18-.96; P = .041) and inflammatory markers were significantly lower in the METRIF arm. Higher body mass index and lower sputum smear grading were associated with faster sputum culture conversion. CONCLUSIONS: The addition of metformin to standard ATT did not hasten sputum culture conversion but diminished excess inflammation, thus reducing lung tissue damage as seen by faster clearance on X-ray and reduced inflammatory markers. CLINICAL TRIALS REGISTRATION: Clinical Trial Registry of India (CTRI/2018/01/011176).
引用
- Padmapriydarsini C, Mamulwar M, Mohan A, et al. Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis. Clin Infect Dis. 2022. PMID: 34849651. doi:10.1093/cid/ciab964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。